Malignant pleural mesothelioma (MPM) is a disease with a dismal prognosis. Currently available treatments have modest results. Therefore, new agents and new treatment strategies are eagerly awaited by patients and clinicians. Preclinical and clinical studies have shown that angiogenesis plays a very important role in MPM. Therefore, a great hope has been placed in the use of anti-angiogenic agents in this disease.

Anti-angiogenic therapies for malignant pleural mesothelioma

Zucali, Paolo Andrea
2012

Abstract

Malignant pleural mesothelioma (MPM) is a disease with a dismal prognosis. Currently available treatments have modest results. Therefore, new agents and new treatment strategies are eagerly awaited by patients and clinicians. Preclinical and clinical studies have shown that angiogenesis plays a very important role in MPM. Therefore, a great hope has been placed in the use of anti-angiogenic agents in this disease.
Angiogenesis Inhibitors
Animals
Antineoplastic Agents
Biomarkers
Clinical Trials as Topic
Drug Delivery Systems
Drug Design
Drug Evaluation, Preclinical
Humans
Mesothelioma
Neovascularization, Pathologic
Pleural Neoplasms
Prognosis
Vascular Endothelial Growth Factor A
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11699/55277
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 13
  • ???jsp.display-item.citation.isi??? 15
social impact